Document Detail

Soluble thrombomodulin antigen in plasma is increased in patients with acute myocardial infarction treated with thrombolytic therapy.
MedLine Citation:
PMID:  8743727     Owner:  NLM     Status:  MEDLINE    
Thrombomodulin (TM) is an integral endothelial cell membrane protein that functions as a cofactor for thrombin mediated activation of protein C. The anticoagulant functions of the protein C system are important in contributing to a hemostatic balance and prevention of thromboembolic disease. It has been suggested that impaired TM cofactor function could also constitute a prothrombotic abnormality leading to thromboembolic diseases. TM exists not only on the surface of endothelial cells but also as soluble fragment(s) circulating in plasma. The concept of a thrombotic occlusion as the critical event in acute myocardial infarction (AMI) forms the rationale for thrombolytic therapy. After successful reperfusion, patients remain at substantial risk for recurrent infarctions due to rethrombosis. The balance between procoagulant and anticoagulant mechanisms in the postthrombolytic phase have not been studied in detail. We have studied whether the plasma levels of soluble TM are influenced by thrombolytic therapy with streptokinase in patients suffering from AMI. Soluble TM concentrations increased significantly by 24 to 48 h after thrombolytic treatment, simultaneously with an increase in C-reactive protein (CRP, a marker of the inflammatory component of the cell damage) and in thio-barbituric acid reactive substances (TBARS, an indirect marker of lipid peroxidation).
A K Ohlin; J Morser; H Ohlin
Related Documents :
10399807 - Spontaneous coronary artery dissection. case report and literature review.
8187367 - High frequency qrs electrocardiography in the detection of reperfusion following thromb...
10084057 - New plasminogen activators: a clinical review.
2521707 - Acute myocardial infarction. treatment in the coronary care unit.
8674267 - Postpericardiotomy syndrome and cardiac tamponade following transvenous pacemaker place...
19482017 - All in the timing: a comparison between the cardioprotection induced by h2s preconditio...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Thrombosis research     Volume:  82     ISSN:  0049-3848     ISO Abbreviation:  Thromb. Res.     Publication Date:  1996 May 
Date Detail:
Created Date:  1996-11-21     Completed Date:  1996-11-21     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0326377     Medline TA:  Thromb Res     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  313-22     Citation Subset:  IM    
Department of Clinical Chemistry, University Hospital, Lund, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acute Disease
C-Reactive Protein / analysis
Fibrinolytic Agents / therapeutic use*
Middle Aged
Myocardial Infarction / blood*,  drug therapy
Streptokinase / therapeutic use*
Thiobarbituric Acid Reactive Substances / analysis
Thrombomodulin / analysis*
Reg. No./Substance:
0/Fibrinolytic Agents; 0/Thiobarbituric Acid Reactive Substances; 0/Thrombomodulin; 9007-41-4/C-Reactive Protein; EC 3.4.-/Streptokinase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effect of active oxygen species scavengers on fibrinolytic activity of some proteinases.
Next Document:  Plasma stimulation of prostacyclin production by rat smooth muscle cells requires previous induction...